Search

Displaying results 9271 - 9280 of 10000 in total
  1. Drug

    VB-201

    go.drugbank.com/drugs/DB15259
    Investigational

    VB-201 is under investigation in clinical trial NCT01001468 (Study to Assess VB-201 in Patients With Psoriasis).

  2. Drug

    Zigakibart

    go.drugbank.com/drugs/DB18892
    Investigational

    Zigakibart is under investigation in clinical trial NCT05852938 (A Study of BION-1301 in Adults With Iga Nephropathy).

  3. Drug

    Ropanicant

    go.drugbank.com/drugs/DB19134
    Investigational

    Ropanicant is under investigation in clinical trial NCT06126497 (Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients).

  4. Drug

    β-Methylfentanyl

    go.drugbank.com/drugs/DB09171
    ExperimentalIllicit

    β-Methylfentanyl is an analgesic of the _opioid_ class. It is an analog of the potent opioid, fentanyl.

  5. Drug

    Murepavadin

    go.drugbank.com/drugs/DB14777
    Investigational

    Murepavadin is under investigation in clinical trial NCT02110459 (Pharmacokinetics and Safety of POL7080 in Patients With Renal Impairment).

  6. Drug

    Topramezone

    go.drugbank.com/drugs/DB14826
    Experimental

    Topramezone is under investigation in clinical trial NCT00559520 (The Role of Preoperative Oral Immunonutrition in Major Vascular Surgery).

  7. Drug

    Telisotuzumab

    go.drugbank.com/drugs/DB14838
    Investigational

    Telisotuzumab is under investigation in clinical trial NCT01472016 (Study of ABT-700 in Subjects With Advanced Solid Tumors).

  8. Drug

    DTX-101

    go.drugbank.com/drugs/DB17699
    Investigational

    DTX-101 is an investigational gene therapy consisting of an adeno-associated virus serotype Rh10 vector encoding the human Factor Ix gene. … It was previously investigated for the treatment of hemophilia B; however, the clinical development of DTX-101 was discontinued.[L46103]

  9. Drug

    GX-19 Vaccine

    go.drugbank.com/drugs/DB15891
    Investigational

    The GX-19 vaccine is a DNA vaccine created by Genexine, Inc. Company in Gyeonggi, Korea[A219758]. … As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels for safety and efficacy[A219758,L16488].

  10. Drug

    Retezorogant

    go.drugbank.com/drugs/DB21592
    Experimental

    The usage of the INN stem '-rogant' in the name indicates that Retezorogant is a retinoic acid receptor-related orphan receptor gamma (RORY) antagonist and inverse agonist. … Retezorogant is a small molecule drug.